Causaly Raises $60 Million In Series B Funding To Catalyze Ai-Powered Preclinical Discovery

Jul 13, 2023•over 2 years ago

Amount Raised

$60 Million

Round Type

series b

United KingdomOther

Investors

Olivier PomelAlex GorskyVisionaries ClubPentech VenturesEbrdMarathon Venture CapitalIndex VenturesIconiq Growth

Description

Causaly, the leading AI platform for biomedical research, closed $60m in Series B funding led by ICONIQ Growth, with participation from Index Ventures, Marathon Venture Capital, EBRD, Pentech Ventures and Visionaries Club. Strategic individuals also participated in the round, including Alex Gorsky (former Chairman and CEO of Johnson & Johnson) and Olivier Pomel (CEO and Co-Founder of Datadog). The latest round comes after the company recently tripled revenue and customers, now serving 12 of the top 20 pharma companies. The investment brings the total funding raised to $93 million, which will be utilized to extend Causaly’s product lead and expand commercial relationships, enabling breakthrough therapeutic innovations faster than ever before.

Company Information

Company

Causaly

Location

2 Underwood Row

United Kingdom

About

Our mission at Causaly is to redefine the boundaries of human discovery by harnessing transformative AI technologies. Founded in 2018, Causaly’s unique AI platform is a powerful catalyst for the modern Life Science research organization, reshaping how data is found, analyzed and applied in critical decision-making processes in drug discovery and development. Supporting a broad range of complex knowledge workflows, our platform accelerates the journey from bench research and laboratory insights to the launch of life-changing therapies.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends